A Phase 3 interventional study of Aripiprazole IM Depot in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 38 sites in 3 countries. Open to participants aged 18 Years to 66 Years. Per ClinicalTrials.gov, last updated 2015-03-31.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.
Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 80th largest by enrollment of the 125 interventional ones that give a count, is one of 6 that started in 2013, is one of 34 in phase 3, and was the 75th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–65
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ages 15–40
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 66 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 10 · Phase 3 38 · Phase 4 56
First in 1998; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is close to the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 130 across the 125 interventional studies. Of the 105 that completed or were terminated, 47 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 67th largest by enrollment of the 111 interventional ones that give a count, is one of 9 that started in 2013, is one of 50 in phase 3, and was the 51st registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
1 of the studies testing aripiprazole in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07547384CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. | 2027-09-05 |
Add it to your calendar (.ics) → With an account.
Among the 126 studies testing aripiprazole in Schizophrenia, from their registry updates:
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The phase 3 Trial 31-12-291 is part of the aripiprazole IM depot clinical development program and has been designed to demonstrate the efficacy and safety of aripiprazole IM depot for the treatment of adults experiencing an acute relapse of schizophrenia. Subjects receive treatment during a 12-week double-blind acute treatment phase. The current trial (31-12-297) will allow the subjects who complete Trial 291 to enter this open label trial at the investigator's discretion, where additional safety and tolerability data will be collected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aripiprazole IM Depot 400 mg or 300 mg once monthly (every 28 days) for 24 weeks
Drug: Aripiprazole IM Depot
Aripiprazole IM Depot 400 mg or 300 mg
Percentage of Participants Reporting Treatment Emergent Adverse Events (TEAEs), Severe TEAEs, Discontinued Investigational Medicinal Product (IMP) Due to AEs, Serious TEAEs and Outcome of Death
A TEAE was defined as an AE that began after the first injection or was continuous from Baseline and was serious, study drug-related, or resulted in death.
Time frame: Baseline to Week 24
Mean Change From Baseline in Suicidal Ideation Intensity Total Score by the Columbia Suicide Severity Rating Scale (C-SSRS)
Data collected from C-SSRS were mapped into C-CASA. The Columbia Classification Algorithm of Suicide Assessment (C-CASA) method and C-SSRS(text in parentheses as said below) were mapped as; 1= completed suicide(completed suicide); 2= suicide attempt(actual attempt); 3= preparatory actions toward imminent suicidal behavior (interrupted attempt, aborted attempt and preparatory acts/behavior); 4= suicidal ideation(wish to die,active suicidal thought, active suicidal thought with method, active suicidal thought with intent,active suicidal thought with plan/intent); 5= self-injurious behavior, intent unknown; 6= not enough information: death; 7= non-suicidal self-injurious behavior(nonsuicidal self-injurious behavior); 8= other accident; psychiatric/medical; 9= not enough information/non-death. C-CASA category 5, 6, 8 and 9 are not applicable. For each item, each participant received an intensity score from 0(none) to 5(worst). Suicidal ideation intensity total score range from 0 to 25.
Time frame: Baseline to Week 24
Mean Change From Baseline by Week by Extrapyramidal Symptoms (EPS) Evaluated Using the Simpson-Angus Scale (SAS)
The EPS rating scales included SAS total score (range 10-50) was the sum of the rating scores for 10 items from the SAS panel. This scale consists of a list of 10 symptoms, each to be rated on a 5-point scale of severity. For each symptom, the rating which best described the patient's condition were, 1= gait; 2= arm dropping; 3= shoulder shaking; 4= elbow rigidity; 5= wrist rigidity; 6= head rotation; 8= tremor; 9= salivation; 10= akathisia.
Time frame: Baseline to Week 24
Mean Change From Baseline by Week by EPS Evaluated Using the Abnormal Involuntary Movement Scale (AIMS)
EPS rating scale included the AIMS movement rating score (range 0-28) was the sum of the rating scores for facial and oral movements (i.e., item 1 - 4), extremity movements (i.e. item 5 - 6), and trunk movements (i.e. item 7). The symptoms for facial and oral movements were 1= muscles of facial expression, 2= lips and perioral area, 3= jaw and 4=tongue; extremity movements were, 5= upper (arms, wrists, hands, fingers), lower (legs, knees, ankles, toes), 7= neck, shoulders, hips). This scale consisted of 10 items, each to be rated on a 4-point scale of severity, and 2 questions to be answered by yes or no. To complete the scale, the patient was observed unobtrusively at rest (e.g., in waiting room). The chair used for this examination was hard, firm one without arms.
Time frame: Baseline to Week 24
Mean Change From Baseline by Week by EPS Evaluated Using Barnes Akathisia Rating Scale (BARS)
The BARS global score (range 0-5) was derived from the global clinical assessment of akathisia from the BARS panel were, 0= absent; 1= questionable; 2= mild akathisia; 3= moderate akathisia; 4= marked akathisia; 5= severe akathisia. Patients were observed while they were seated and then standing (for a minimum of 2 minutes in each position). Symptoms were observed in other situations (e.g., while engaged in neutral conversation, engaged in activity on the ward) was also rated.
Time frame: Baseline to Week 24
Mean Change in Body Temperature From Baseline in All Participants.
The body temperature, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure, and respiratory rate that were identified based on pre-defined criteria.
Time frame: Baseline to last visit
Mean Change in Heart Rate Supine From Baseline in All Participants.
The heart rate supine, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure, and respiratory rate that were identified based on pre-defined criteria.
Time frame: Baseline to last visit
Mean Change in Systolic Supine Blood Pressure (BP) From Baseline in All Participants.
The systolic supine BP, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure, and respiratory rate that were identified based on pre-defined criteria.
Time frame: Baseline to last visit
Mean Change in Diastolic Supine BP From Baseline in All Participants.
The diastolic supine BP, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure and respiratory rate that were identified based on pre-defined criteria.
Time frame: Baseline to last visit
Mean Change in Heart Rate From Baseline in All Participants.
The heart rate sitting, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure and respiratory rate that were identified based on pre-defined criteria. Orthostatic assessments of blood pressure and heart rate were made after the participant was supine for at least 5 minutes and again after the participant was sitting for approximately 2 minutes.
Time frame: Baseline to last visit
Mean Change in Systolic BP From Baseline in All Participants.
The systolic sitting BP, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure and respiratory rate that were identified based on pre-defined criteria. Orthostatic assessments of blood pressure and heart rate were made after the participant was supine for at least 5 minutes and again after the participant was sitting for approximately 2 minutes.
Time frame: Baseline to last visit
Mean Change in Diastolic BP From Baseline in All Participants.
The diastolic sitting BP, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure and respiratory rate that were identified based on pre-defined criteria. Orthostatic assessments of blood pressure and heart rate were made after the participant was supine for at least 5 minutes and again after the participant was sitting for approximately 2 minutes.
Time frame: Baseline to last visit
Mean Change in Ventricular Rate From Baseline in All Participants.
The measurement ventricular rate is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.
Time frame: Baseline to last visit
Mean Change in PR Interval From Baseline in All Participants.
The measurement PR interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.
Time frame: Baseline to last visit
Mean Change in RR Interval From Baseline in All Participants.
The measurement RR interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.
Time frame: Baseline to last visit
Mean Change in QRS Interval From Baseline in All Participants.
The measurement QRS interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.
Time frame: Baseline to last visit
Mean Change in QT Interval From Baseline in All Participants.
The measurement QT interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.
Time frame: Baseline to last visit
Mean Change in QTcB Interval From Baseline in All Participants.
The measurement QTcB interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.
Time frame: Baseline to last visit
Mean Change in QTcF Interval From Baseline in All Participants.
The measurement QTcF interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.
Time frame: Baseline to last visit
Mean Change in QTcN Interval From Baseline in All Participants.
The measurement QTcN interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.
Time frame: Baseline to last visit
Mean Change in Clinically Relevant Body Weight Changes From Baseline in All Participants.
Clinically relevant body weight changes was one of the primary parameters to measure the safety and tolerability of individual participants. Each participant's body mass index (BMI) kilogram per square meter (kg/m2) were calculated from the screening. Body weight, BMI, and waist circumference changes were evaluated by calculating mean change from Baseline and by tabulating the incidence of ≥7% weight gain or loss.
Time frame: Baseline to last visit
Mean Change in Clinically Relevant Body Mass Index From Baseline in All Participants.
Clinically relevant body mass index was one of the primary parameters to measure the safety and tolerability of individual participants. Each participant's body mass index (BMI) kilogram per square meter (kg/m2) were calculated from the screening. Body weight, BMI, and waist circumference changes were evaluated by calculating mean change from Baseline and by tabulating the incidence of ≥7% weight gain or loss.
Time frame: Baseline to last visit
Mean Change in Clinically Relevant Waist Circumference From Baseline in All Participants.
Clinically relevant waist circumference was one of the primary parameters to measure the safety and tolerability of individual participants. Each participant's body mass index (BMI) kilogram per square meter (kg/m2) were calculated from the screening. Body weight, BMI, and waist circumference changes were evaluated by calculating mean change from Baseline and by tabulating the incidence of ≥7% weight gain or loss.
Time frame: Baseline to last visit
Number of Participants With Clinically Relevant Laboratory Values.
The laboratory values were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria.
Time frame: Baseline to last visit
Number of Participants With Clinically Relevant Physical Examination.
The physical examination evaluation was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in the following body systems: head, ears, eyes, nose, and throat; thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae.
Time frame: Baseline to last visit
A multicenter, open-label, single-arm rollover trial designed to demonstrate the safety of aripiprazole intramuscular (IM) depot \[400 or 300 milligrams (mg)\] for the acute treatment of participants with schizophrenia, who met completion criteria in the registration trial NCT01663532. 74 participants were enrolled in this trial.
| Milestone | Aripiprazole IM Depot 400/300 mg |
|---|---|
| Started | 74 |
| Completed | 45 |
| Not completed | 29 |
| Withdrew: Lost to follow-up | 9 |
| Withdrew: Adverse event | 6 |
| Withdrew: Subject met withdrawal criteria | 5 |
| Withdrew: Withdrawal by subject | 7 |
| Withdrew: Lack of efficacy | 2 |
A TEAE was defined as an AE that began after the first injection or was continuous from Baseline and was serious, study drug-related, or resulted in death.
| Percentage of participants | Aripiprazole IM Depot 400/300 mg |
|---|---|
| Participants with TEAEs | 66.2 |
| Participants with serious TEAEs | 6.8 |
| Participants with severe TEAEs | 8.1 |
| Participants discontinued IMP due to AEs | 8.1 |
| Deaths | 0.0 |
Data collected from C-SSRS were mapped into C-CASA. The Columbia Classification Algorithm of Suicide Assessment (C-CASA) method and C-SSRS(text in parentheses as said below) were mapped as; 1= completed suicide(completed suicide); 2= suicide attempt(actual attempt); 3= preparatory actions toward imminent suicidal behavior (interrupted attempt, aborted attempt and preparatory acts/behavior); 4= suicidal ideation(wish to die,active suicidal thought, active suicidal thought with method, active suicidal thought with intent,active suicidal thought with plan/intent); 5= self-injurious behavior, intent unknown; 6= not enough information: death; 7= non-suicidal self-injurious behavior(nonsuicidal self-injurious behavior); 8= other accident; psychiatric/medical; 9= not enough information/non-death. C-CASA category 5, 6, 8 and 9 are not applicable. For each item, each participant received an intensity score from 0(none) to 5(worst). Suicidal ideation intensity total score range from 0 to 25.
| Units on a scale | Aripiprazole IM Depot 400/300 mg |
|---|---|
| Week 4 (N= 69) | -0.1 ± 2.3 |
| Week 8 (N= 61) | -0.1 ± 2.2 |
| Week 12 (N= 57) | -0.3 ± 2.0 |
| Week 16 (N= 52) | 0.7 ± 4.7 |
| Week 20 (N= 44) | 0.3 ± 2.0 |
| Week 24 (N= 45) | 0.0 ± 0.0 |
| Last Visit (N= 71) | 0.6 ± 4.2 |
The EPS rating scales included SAS total score (range 10-50) was the sum of the rating scores for 10 items from the SAS panel. This scale consists of a list of 10 symptoms, each to be rated on a 5-point scale of severity. For each symptom, the rating which best described the patient's condition were, 1= gait; 2= arm dropping; 3= shoulder shaking; 4= elbow rigidity; 5= wrist rigidity; 6= head rotation; 8= tremor; 9= salivation; 10= akathisia.
| Units on a scale | Aripiprazole IM Depot 400/300 mg |
|---|---|
| Week 12 (N= 66) | 0.19 ± 1.51 |
| Week 24 (N= 70) | 0.04 ± 1.62 |
EPS rating scale included the AIMS movement rating score (range 0-28) was the sum of the rating scores for facial and oral movements (i.e., item 1 - 4), extremity movements (i.e. item 5 - 6), and trunk movements (i.e. item 7). The symptoms for facial and oral movements were 1= muscles of facial expression, 2= lips and perioral area, 3= jaw and 4=tongue; extremity movements were, 5= upper (arms, wrists, hands, fingers), lower (legs, knees, ankles, toes), 7= neck, shoulders, hips). This scale consisted of 10 items, each to be rated on a 4-point scale of severity, and 2 questions to be answered by yes or no. To complete the scale, the patient was observed unobtrusively at rest (e.g., in waiting room). The chair used for this examination was hard, firm one without arms.
| Units on a scale | Aripiprazole IM Depot 400/300 mg |
|---|---|
| Week 12 (N= 65) | -0.06 ± 0.81 |
| Week 24 (N= 70) | 0.07 ± 1.28 |
The BARS global score (range 0-5) was derived from the global clinical assessment of akathisia from the BARS panel were, 0= absent; 1= questionable; 2= mild akathisia; 3= moderate akathisia; 4= marked akathisia; 5= severe akathisia. Patients were observed while they were seated and then standing (for a minimum of 2 minutes in each position). Symptoms were observed in other situations (e.g., while engaged in neutral conversation, engaged in activity on the ward) was also rated.
| Units on a scale | Aripiprazole IM Depot 400/300 mg |
|---|---|
| Week 12 (N= 65) | 0.19 ± 0.73 |
| Week 24 (N= 70) | 0.14 ± 0.91 |
The body temperature, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure, and respiratory rate that were identified based on pre-defined criteria.
| °C | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 4 (N= 69) | 0.1 ± 0.4 |
| Week 8 (N= 61) | -0.0 ± 0.4 |
| Week 12 (N= 58) | 0.0 ± 0.4 |
| Week 16 (N= 53) | 0.0 ± 0.3 |
| Week 20 (N= 44) | 0.1 ± 0.4 |
| Week 24 (N= 45) | 0.1 ± 0.4 |
| Last visit (N= 72) | 0.0 ± 0.4 |
The heart rate supine, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure, and respiratory rate that were identified based on pre-defined criteria.
| beats/min | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 4 (N= 69) | 3.8 ± 10.9 |
| Week 8 (N= 61) | 2.3 ± 11.2 |
| Week 12 (N= 58) | 1.3 ± 10.8 |
| Week 16 (N= 53) | 4.7 ± 12.0 |
| Week 20 (N= 44) | 3.6 ± 9.8 |
| Week 24 (N= 45) | 1.7 ± 12.7 |
| Last visit (N= 72) | 3.4 ± 12.1 |
The systolic supine BP, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure, and respiratory rate that were identified based on pre-defined criteria.
| mmHg | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 4 (N= 69) | 1.9 ± 12.8 |
| Week 8 (N= 61) | 1.3 ± 12.2 |
| Week 12 (N= 58) | -0.2 ± 12.4 |
| Week 16 (N= 53) | 2.0 ± 12.4 |
| Week 20 (N= 44) | 4.8 ± 12.8 |
| Week 24 (N= 45) | 0.7 ± 11.3 |
| Last visit (N= 72) | 0.4 ± 13.1 |
The diastolic supine BP, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure and respiratory rate that were identified based on pre-defined criteria.
| mmHg | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 4 (N= 69) | 0.1 ± 8.6 |
| Week 8 (N= 61) | -1.3 ± 8.1 |
| Week 12 (N= 58) | -0.9 ± 7.7 |
| Week 16 (N= 53) | 0.3 ± 8.6 |
| Week 20 (N= 44) | -0.0 ± 9.6 |
| Week 24 (N= 45) | 0.4 ± 9.7 |
| Last visit (N= 72) | 0.5 ± 9.9 |
The heart rate sitting, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure and respiratory rate that were identified based on pre-defined criteria. Orthostatic assessments of blood pressure and heart rate were made after the participant was supine for at least 5 minutes and again after the participant was sitting for approximately 2 minutes.
| beats/min | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 4 (N= 69) | 1.2 ± 9.1 |
| Week 8 (N= 61) | 1.4 ± 10.1 |
| Week 12 (N= 58) | -1.1 ± 10.8 |
| Week 16 (N= 53) | 4.3 ± 12.0 |
| Week 20 (N= 44) | 3.3 ± 10.1 |
| Week 24 (N= 45) | 0.6 ± 13.6 |
| Last visit (N= 72) | 1.9 ± 13.0 |
The systolic sitting BP, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure and respiratory rate that were identified based on pre-defined criteria. Orthostatic assessments of blood pressure and heart rate were made after the participant was supine for at least 5 minutes and again after the participant was sitting for approximately 2 minutes.
| mmHg | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 4 (N= 69) | -0.1 ± 13.0 |
| Week 8 (N= 61) | -0.3 ± 11.3 |
| Week 12 (N= 58) | -0.7 ± 11.3 |
| Week 16 (N= 53) | 1.6 ± 12.1 |
| Week 20 (N= 44) | 1.0 ± 11.5 |
| Week 24 (N= 45) | -0.4 ± 12.5 |
| Last visit (N= 72) | -0.7 ± 13.4 |
The diastolic sitting BP, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure and respiratory rate that were identified based on pre-defined criteria. Orthostatic assessments of blood pressure and heart rate were made after the participant was supine for at least 5 minutes and again after the participant was sitting for approximately 2 minutes.
| mmHg | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 4 (N= 69) | -0.9 ± 9.7 |
| Week 8 (N= 61) | -1.7 ± 9.4 |
| Week 12 (N= 58) | -0.2 ± 7.9 |
| Week 16 (N= 53) | 0.8 ± 7.8 |
| Week 20 (N= 44) | -0.2 ± 10.0 |
| Week 24 (N= 45) | 0.4 ± 9.8 |
| Last visit (N= 72) | 1.4 ± 10.0 |
The measurement ventricular rate is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.
| Beats/min | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 12 (N= 56) | -1.5 ± 12.0 |
| Week 24 (N= 43) | -1.1 ± 12.3 |
| Last visit (N= 70) | -0.1 ± 13.7 |
The measurement PR interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.
| msec | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 12 (N= 56) | 3.5 ± 11.1 |
| Week 24 (N= 43) | 0.5 ± 12.5 |
| Last visit (N= 70) | 0.9 ± 11.6 |
The measurement RR interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.
| msec | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 12 (N= 56) | 23.7 ± 140.9 |
| Week 24 (N= 43) | 23.3 ± 152.2 |
| Last visit (N= 70) | 8.0 ± 158.4 |
The measurement QRS interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.
| msec | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 12 (N= 56) | -0.1 ± 5.0 |
| Week 24 (N= 43) | 0.4 ± 5.3 |
| Last visit (N= 70) | 0.0 ± 5.7 |
The measurement QT interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.
| msec | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 12 (N= 56) | 3.1 ± 21.5 |
| Week 24 (N= 43) | 1.5 ± 24.9 |
| Last visit (N= 70) | 1.0 ± 25.7 |
The measurement QTcB interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.
| msec | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 12 (N= 56) | -1.6 ± 20.2 |
| Week 24 (N= 43) | -2.4 ± 19.4 |
| Last visit (N= 70) | 0.3 ± 19.0 |
The measurement QTcF interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.
| msec | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 12 (N= 56) | -0.2 ± 13.9 |
| Week 24 (N= 43) | -1.3 ± 14.0 |
| Last visit (N= 70) | 0.3 ± 12.9 |
The measurement QTcN interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.
| msec | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 12 (N= 56) | -0.5 ± 14.7 |
| Week 24 (N= 43) | -1.7 ± 14.3 |
| Last visit (N= 70) | 0.3 ± 13.4 |
Clinically relevant body weight changes was one of the primary parameters to measure the safety and tolerability of individual participants. Each participant's body mass index (BMI) kilogram per square meter (kg/m2) were calculated from the screening. Body weight, BMI, and waist circumference changes were evaluated by calculating mean change from Baseline and by tabulating the incidence of ≥7% weight gain or loss.
| Kg | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 12 (N= 57) | -0.1 ± 4.5 |
| Week 24 (N= 44) | 1.3 ± 6.0 |
| Last visit (N= 71) | 0.5 ± 5.8 |
Clinically relevant body mass index was one of the primary parameters to measure the safety and tolerability of individual participants. Each participant's body mass index (BMI) kilogram per square meter (kg/m2) were calculated from the screening. Body weight, BMI, and waist circumference changes were evaluated by calculating mean change from Baseline and by tabulating the incidence of ≥7% weight gain or loss.
| Kg/m2 | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 12 (N= 57) | -0.0 ± 1.5 |
| Week 24 (N= 44) | 0.5 ± 2.0 |
| Last visit (N= 71) | 0.2 ± 1.9 |
Clinically relevant waist circumference was one of the primary parameters to measure the safety and tolerability of individual participants. Each participant's body mass index (BMI) kilogram per square meter (kg/m2) were calculated from the screening. Body weight, BMI, and waist circumference changes were evaluated by calculating mean change from Baseline and by tabulating the incidence of ≥7% weight gain or loss.
| cm | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Week 24 (N= 44) | 1.6 ± 6.6 |
| Last visit (N= 64) | 1.3 ± 6.0 |
The laboratory values were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria.
| participants | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Number of Participants With Clinically Relevant Laboratory Values. | 0 |
The physical examination evaluation was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in the following body systems: head, ears, eyes, nose, and throat; thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae.
| participants | Aripiprazole IM Depot 400/ 300 mg |
|---|---|
| Number of Participants With Clinically Relevant Physical Examination. | 0 |
Collected over AEs were recorded from the time the ICF was signed until follow-up for safety 14 (±2) days after the last trial visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aripiprazole IM Depot 400/300 mg | — | 5/74 (6.8%) | 40/74 (54.1%) |
| Event | Aripiprazole IM Depot 400/300 mg |
|---|---|
| DepressionPsychiatric disorders | 2/74 |
| SchizophreniaPsychiatric disorders | 2/74 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/74 |
| Suicidal ideationPsychiatric disorders | 1/74 |
| Event | Aripiprazole IM Depot 400/300 mg |
|---|---|
| Weight increasedInvestigations | 22/74 |
| AkathisiaNervous system disorders | 9/74 |
| Weight decreasedInvestigations | 6/74 |
| HeadacheNervous system disorders | 6/74 |
| HyperlipidaemiaMetabolism and nutrition disorders | 4/74 |
| Age, Continuous(Years) | Aripiprazole IM Depot 400/300 mg |
|---|---|
| Mean | 43.0 ± 11.7 |
| Sex: Female, Male(Participants) | Aripiprazole IM Depot 400/300 mg |
|---|---|
| Female | 18 |
| Male | 56 |
The record gives a start of Jan 2013, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →